China R&D Reader

2009年世界制药巨头紧抓着我国医改之政策，纷纷抢占我国医药市场份额。寄望业内人士要保持足够的警醒，若国内市场我们不再想法保全的话，未来几年，国内医药市场也将无立足之地。

CRO Industry Draws Biomedical Investors to Asia
Battered by economic uncertainty and under pressure to deliver better medical products in more cost-effective ways, pharmaceutical companies are increasingly driven to outsource their research and development to clinical research organisations (CROs) in Asia. This trend in the biomedical sector is poised to make China one of the most [...]

The CRO market in China was $186 million in 2007, according to a recent report from PricewaterhouseCoopers. That number represented growth of 38% from the year before, an increase that was mainly driven by outsourcing from international firms rather than domestic biopharmas. In the future, a CAGR estimated at 33% for the industry will bring [...]

The activity of local and international firms establishing preclinical testing services to good laboratory practice (GLP) standards in Asia continues to gain momentum.
Quest Pharmaceutical Services (QPS) has announced the formation of a partnership with Japanese firm Integra to bring its preclinical and clinical laboratory testing services to the country.
The company is already operating these services [...]

Excerpted from Anderson’s book International Patient Recruitment Regulatory Guidelines, Customs and Practices.
Based on information gathered from several sources, it appears that clinical trial subjects in China are recruited in a limited number of ways, starting with heavy reliance on the investigator to tell appropriate patients about the study, followed by the use of posters and [...]

China is one of the best destinations to outsource preclinical work, delegates heard at this year’s CPhI trade how in Milan.
“The preclinical challenge is having the right research models regarding the safety and protection of animals, but no matter how much care is taken by western labs, they are plagued by protest groups,” DA Prasanna, [...]

China topped a new list of the most attractive low-cost global locations to run clinical trials outside the US.
India and Russia trailed China in the poll, with Brazil and Czech Republic following closely behind.
Clinical trials account for two thirds of the development cost for new drugs and offshoring to locations outside the US is becoming [...]